Abstract
Objective: The impridone ONC201 (Oncoceutics), a dopamine receptor-2 antagonist, has antitumorigenic effects in preclinical studies of endometrial cancer (EC) and is already in phase 2 clinical trials for EC. ONC206, a derivative of ONC201 that shares the imipridone core structure, exhibits distinct receptor pharmacology and nanomolar potency. Thus, we evaluated the antitumorigenic effects of ONC206 in human EC cell lines and the LKB1fl/flp53fl/fl genetically engineered mouse model of endometrioid EC.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
